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Abstract 
Therapeutic angiogenesis is a relatively new medical strategy in the field of cardiovascular diseases. 
The underpinning concept is that angiogenic growth factors or proangiogenic cells could be 
exploited therapeutically in cardiovascular patients to enhance native revascularization responses to 
an ischemic insult, thereby accelerating tissue healing. The initial enthusiasm generated by 
preclinical studies has been tempered by the modest success of clinical trials assessing therapeutic 
angiogenesis. Similarly, proangiogenic cell therapy has so far not maintained the original promises. 
Intriguingly, the current trend is to consider regeneration as a prerogative of the youngest organism. 
Consequentially, the embryonic and foetal models are attracting much attention for clinical 
translation into corrective modalities in the adulthood. Scientists seem to undervalue the lesson 
from Mother Nature, e.g. all humans are born young but very few achieve the goal of an 
exceptional healthy longevity. Either natural experimentation is driven by a supreme intelligence or 
stochastic phenomena, one has to accept the evidence that healthy longevity is the fruit of an 
evolutionary process lasting million years. It is therefore extremely likely that results of this natural 
experimentation are more reliable and translatable than the intensive, but very short human 
investigation on mechanisms governing repair and regeneration. With this preamble in mind, here 
we propose to shift the focus from the very beginning to the very end of human life and thus capture 
the secret of prolonged health span to improve well-being in the adulthood. 
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Abbreviations  
BPIFB4: bactericidal/permeability-increasing fold-containing family B member 
CVD: cardio vascular disease 
CHD: coronary heart disease 
MI: myocardial infarction 
HF: heart failure 
LI: limb ischemia 
AD: Alzheimer disease 
AAV: adeno associated virus 
APOE: apolipoprotein E 
eNOS: endothelial nitric oxide synthase 
nNOS neuronal nitric oxide synthase  
iNOS: inducible nitric oxide synthase 
VEGF-A: vascular endothelial growth factor-A 
LLIs: long-living individuals 
GC: genetic component 
SNPs: single nucleotide polymorphisms 
FOXO3A: forkhead box O3A 
GWAS: genome-wide association studies  
LAV: longevity associated variant 
RV: rare variant  
WT: wild type 
SOD: Superoxide dismutase  
ER: endoplasmic reticulum 
UPR: unfolding protein response 
MNC: mononuclear cell 
SDF-1: stromal cell-derived factor 1 
MCP-1: monocyte chemoattractant protein-1 
BH4: tetrahydrobiopterin  
BH2: dihydrobiopterin 
RNS: nitric radical species  
ROS: reactive oxygen species 
HSPs: heat shock proteins  
NO: nitric oxide 
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cGMP: cyclic guanosine monophosphate 
PKB: protein kinase B 
PKA: protein kinase A 
HSP90: heat shock protein 90 
L-NAME: N-nitro-L-arginine methyl ester  
PAD: peripheral artery disease 
CLI: critical limb ischemia  
L-arg: L-arginine  
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1. Introduction 
There are an estimated 7 million people living with cardiovascular disease (CVD) in the UK and 
160,000 people die each year because of CVD. Coronary heart disease (CHD) caused by the 
narrowing of arteries that feed the heart is the UK's single biggest killer, being responsible for 
~73,000 deaths each year, an average of 200 people each day. Acute myocardial infarction (MI), 
which is caused by the occlusion of a coronary artery, represents the most harmful form of CHD. 
Most of the current treatments are palliative, i.e. they reduce symptoms associated with heart 
dysfunction, without providing a definitive repair. Consequently, CHD patients undergo a 
progressive decline in the pumping function of the heart that ultimately leads to heart failure (HF). 
Today, post-infarct HF is the leading cause of invalidity, hospitalization, and mortality in patients 
over 65. Limb ischemia (LI), is also caused by arterial occlusion and manifests as claudication, foot 
ulcers, and gangrene. Revascularization by angioplasty is often unfeasible or ineffective, hence 
many LI patients are left with no therapeutic option rather than foot amputation, which is associated 
with a yearly mortality rate >25% (1). 
Regenerative medicine aims to provide a definitive treatment of ischemic complications by 
promoting endogenous mechanisms of repair and delivering supply-side boosts of cells, genes, or 
proteins. Unfortunately, both gene therapy and cell therapy failed to achieve the initial promises and 
researchers are now trying to understand the reasons for the unsuccessful translation of preclinical 
studies. In addition, there is a growing interest in untangling the mechanisms that allow an efficient 
regeneration during early stages of the life, but are attenuated with aging.  
A novel way to pursue an effective regenerative product would be to start from a solid 
genetic understanding of the causes of disease and its predisposing factors. The most important risk 
factor for CVD is aging, and, recently, huge efforts have been done to halt the aging process in 
order to prevent cardiovascular complications. On the other hand, CVDs represent the most 
important cause of death for both middle-age and elderly people. For instance, a follow-up study on 
a population of 14345 individuals of 44 years old men showed that 300 out of the 914 death for all 
causes died for CVD in the follow-up of 11.4 years. Men who maintained or improved fitness had 
30% and 40% lower risk of corresponding mortality, respectively (2). This data could be interpreted 
in two different ways: 1) exercise training is the only possible way to reduce mortality; 2) among 
people analyzed, the ones genetically predisposed to live longer are biologically younger and thus 
have a better attitude to fitness that further contributes to the reduced mortality. The second key of 
interpretation is also in keeping with a fundamental shift in the regenerative medicine strategy. 
While most attention has been focused on correcting mechanistic targets responsible for failed 
regeneration, a more effective approach would be to determine and exploit the factors that allow 
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some individuals to avoid CVD or cope better with CVD when it occurs. This is the case of the 
long-living individuals (LLIs), i.e. the small number of (1/5000 born) people that survive to be 100 
years old, and their closest relatives and offspring, which have higher probability to live long and 
healthy (3, 4). Centenarians are either healthy or survivors of diseases of aging, such as diabetes, 
cancer, and CVD. Thus, studying the centenarians’ genetic code could disentangle how these 
individuals delay aging and escape or experience attenuated forms of CVDs.  
In this review, we will discuss mechanisms of regenerative angiogenesis instrumental to 
therapeutic revascularization of ischemic tissues. In particular, we will focus on the novel approach 
of interrogating the genetics of exceptional longevity to unravel regulators of vascular function that 
could be exploited in effective proangiogenic therapies. 
 
2. Reparative angiogenesis for CVD 
The knowledge of the different phases of the angiogenic process, the cells involved, and the factors 
released have been exploited to treat aging-related diseases in which angiogenesis is dysfunctional. 
The process of vessel remodeling in the adult occurs through sprouting of new vessels from existing 
ones. This process known as angiogenesis is guided by endothelial cells (ECs) that switch from a 
quiescent to an active state in the presence of proangiogenic factors as reviewed in (5). During the 
process, specialized ECs known as tip ECs, following proangiogenic cues, move towards the zone 
that needs to be vascularized. The cells behind the tip are known as stalk ECs and form the body of 
the nascent vessel. In addition, CD34+ cells derived from bone marrow (BM) and released in the 
circulatory system upon activation by physical or chemical stimuli, formerly known as endothelial 
progenitor cells (EPCs), also contribute to the process mostly via the paracrine activation of resident 
ECs (6).  
The possibility to restore angiogenesis therapeutically was applied for the treatment of 
coronary artery disease (CAD) and peripheral vascular disease (PVD) especially through the 
administration of proangiogenic factors like VEGF-A (7). Indeed vascular endothelial growth 
factor-A (VEGF-A) triggers angiogenesis and also improves vessel function through the activation 
of eNOS (with the consequent production of NO) and activation of prostacyclin (PGI2) (8). 
However, despite the success of preclinical studies in animals, clinical trials in humans showed 
poor or no efficacy. The same results were obtained using other angiogenic factors like FGF-2 (9) 
or other technologies like gene therapy methods (10). Most of the negative outcomes are related to 
bias in the study design, but also to the fact that angiogenic factors activity is more complex than 
expected. For instance VEGF per se is not sufficient to maintain vessels stabilized for a long time. 
In addition, the VEGF dosage should be finely tuned to avoid aberrant or poor angiogenesis (11). 
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The modulation in angiogenesis through cell therapy was also tested using BM-derived cells. These 
studies demonstrated that transplantation or chemokine-induced mobilization of BM cells in 
patients with CAD (reviewed in (12)) or PAD (13) improve ischemic tissue functions although only 
modestly. However, BM cells are not homogeneous as they include hematopoietic (CD45+) and so-
called endothelial progenitors (CD34+) as well as non-hematopoietic (CD45-) cells. Therefore, 
better isolation protocols and more specific markers are needed. Furthermore, more efforts should 
be done to better understand their mechanisms of action, including physical or paracrine 
interactions with resident cells. In addition, it is necessary to consider that there are inter-individual 
differences in the level of these cell populations which are affected by aging especially when 
associated with diseases like diabetes, hypertension and others (14). In this complex context, new 
tools to promote a controlled and physiologic angiogenesis are needed. 
 
3. ENOS is a central player in cardiovascular homeostasis  
Since the discovery of angiogenic growth factors, it was clear that signaling pathways converge on 
NO production by eNOS in the endothelium and in circulating angiogenic cells (22). In this section, 
we briefly summarize current evidence on how eNOS activity impacts on the health of the 
cardiovascular system, and how researchers have attempted until now with a various degree of 
success to intervene on eNOS to improve vascular function. 
 
3.1 The eNOS signaling pathway and the control of angiogenesis 
ENOS is the endothelial-specific form of a family of Ca2+-dependent enzymes that regulate NO 
production from L-arginine. In addition to endothelial cells, eNOS is present on circulating blood 
cells, including circulating angiogenic MNCs, and on circulating microparticles, therefore its 
regulation impacts on the overall homeostasis of the vascular tree controlling blood flow restoration 
via angiogenesis, vasculogenesis, and arteriogenesis (23-26). Together with neuronal NOS (nNOS), 
eNOS is constitutively expressed. On the other hand, a third form of NOS, inducible NOS (iNOS), 
is produced in response to insults in monocytes/macrophages, but also in MNCs with angiogenic 
activity, with recent evidences pointing to a potential role of iNOS in the control of angiogenesis 
(27-29).  
The enzymatic function of NOS is modulated by co-factor-mediated dimerization and by 
selective phosphorylation (30, 31). Lack of functional co-factors, tetrahydrobiopterin (BH4) being 
the crucial one, impairs dimerization, with the consequent switch from NO generation to superoxide 
anions production, a process known as NOS uncoupling (32). BH4 oxidation generates 
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dihydrobiopterin (BH2) that in turn contributes to uncoupling (33). Since BH2 competes with BH4 
for eNOS binding, the ratio BH4:BH2 becomes central in coupling (34). 
The vascular endothelium is the primary target of NO that 1) regulates vascular tone and cell 
migration, 2) has an antithrombotic effect, and 3) modulates inflammation (35). The abrogation of 
NO production is linked to alterations in endothelial function, consisting in vessel rigidity, 
increased the adhesiveness of endothelial cells, increased inflammation, and risk of thrombi 
formation (36). Such a condition, known as endothelial dysfunction or endothelial activation, is a 
hallmark of many CVDs. ENOS plays a central role in endothelial homeostasis since it can either 
produce NO contributing to endothelium quiescence or generate reactive oxygen species (ROS) 
thus triggering endothelium activation. Under certain circumstances, the eNOS switch from an NO 
producing to an ROS-producing enzyme is advantageous to implement host defense responses to 
infections, but a persistent ROS production becomes detrimental when exceeding the ROS 
detoxifying machinery of the cell (36). ROS exacerbate endothelial activation by reacting with NO 
to produce nitric radical species (RNS) (37), thus leading to eNOS uncoupling (38). The functional 
alterations of the vascular endothelium reflect on the functionality of entire organs and tissues being 
the cause of disease conditions. ENOS activation is strictly related to angiogenesis. Indeed, 
signaling pathways activated by proangiogenic factors leads to NO formation via eNOS activation 
(8, 39). Generated NO affects also vascular smooth muscle cells biological function contributing to 
vessel relaxation needed for efficient angiogenesis and arteriogenesis. Of note, the NOS inhibitor 
N-nitro-L-arginine methyl ester (L-NAME) is able to block VEGF-mediated angiogenic response 
(40). Moreover, in eNOS knockout mice, ischemic neovascularization is impaired with VEGF 
administration being unable to restore it (35). 
Further supporting the central role of eNOS in vascular regeneration, eNOS knockout mice, 
and L-NAME treated mice show impaired proangiogenic cell mobilization from the bone marrow in 
response to exercise training (41). These proangiogenic cells are also dependent on eNOS for their 
efficient functionality in the vascularization process (42, 43). 
 
3.2 ENOS/NO-based therapies for vascular diseases 
ENOS is crucial for blood flow restoration upon ischemia due to its ability to control angiogenesis 
by inducing EC proliferation and migration, vasculogenesis via activation of circulating 
proangiogenic cell migration, and arteriogenesis by NO-mediated vasodilation (44). Moreover 
improving eNOS/NO system may be the basis of treatment for most if not all the diseases of the 
cardiovascular system as briefly described below. NO availability is fundamental to prevent 
atherosclerosis development and progression. However, the positive effect of dietary 
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supplementation with L-arginine in animal models appears not to be long term effective. This may 
be due to eNOS uncoupling and consequent generation of counterproductive anions. NO unbalance 
also affects the coronary arteries, which loose a proper vasodilatory activity and become prone to 
atherosclerotic remodeling. Reduced expression of eNOS was observed in the endothelium of 
coronary vessels of patients with HF (45). In addition, NO availability is instrumental to the 
outcome of patients with acute MI (46). However, rescuing cardiac function by NO after MI needs 
a fine tuning of eNOS activity, as pointed out by the evidence of a detrimental effect of bearing 
high levels of eNOS activity in transgenic mouse models (47). 
Of note, polymorphisms in eNOS gene have been reported. The 786T/C polymorphism in 
the promoter of the eNOS is associated with decreased enzyme abundance and cardiovascular 
mortality (48). In addition, studies on the three NOS isoforms documented the existence of an 
association between polymorphic variants of eNOS, nNOS and iNOS and susceptibility to CHD 
(49). 
From all of the above, it is clear why several lines of research were developed in the attempt 
of improving NO generation by eNOS or providing NO to the vasculature. Therapeutic strategies 
aimed at recovering functional eNOS coupling are based on antioxidant treatments combined to 
BH4 administration (50, 51). Infusion of BH4 in patients with hypercholesterolemia or type II 
diabetes proved to restore-NO mediated vasodilation, but this approach may hide potential negative 
side effect of altering BH4:BH2 ratio (52-54). Statins represent a powerful tool to improve NO 
generation since their use results in BH4 promotion and eNOS phosphorylation through AKT and 
PKA activation (55). In addition to ameliorating endothelial dysfunction in diabetics, statins and 
thiazolidinediones are effective in improving circulating proangiogenic cell function and number 
(56-58). NO donor drugs have been developed, as for example S-nitrosothiols that have been 
effectively studied in trials using coated stent and other devices to prevent neointima formation 
(59). Combining the beneficial effect of a statin with NO donor approach, the insertion of an NO-
donating moiety to a different class of drugs has been investigated with successful results for 
ischemic vascular regeneration as documented by our group and others (60, 61). 
 
4. Genetic approaches to unravel the cause of exceptional longevity  
Genetic studies on exceptional longevity have so far disclosed the presence of protective variants 
that buffer the effect of deleterious variants (15). This could explain why, with the exception of 
apolipoprotein E (APOE) epsilon 4, an allele that is associated with increased risk of CVD and 
Alzheimer disease (AD), no risk factors have been associated with reduced risk of reaching human 
exceptional longevity (16). A possible explanation of why, despite the buffering role of protective 
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variants, APOE isoform epsilon 4 negatively impact on exceptional longevity, is its interference 
with stem cell survival (17), that could also influence the susceptibility to, and severity of CVD and 
AD.  
Dealing with genetics of complex traits is not easy, since association of a given allele and a 
phenotype is often not replicated in independent studies and this could be related to lack of power 
of the study, which in turn depends on the number of hypotheses tested, the population size 
adopted, and the frequency of the polymorphism interrogated (18). In addition, genetic admixture 
between cases and controls inflated the results generating false positives, a problem now avoided by 
the genetic component (GC) analysis based on the investigation of the entire genome trough chips 
(see below). While candidate genetic studies, being hypothesis-driven, loose most of their novelty 
(see for example APOE and forkhead box O3-FOXO3A), Genome-Wide-Association-Studies 
(GWAS) and now full-genome re-sequencing could unravel completely unexpected new players. 
Unfortunately, especially with re-sequencing, millions of genetic variants are interrogated making 
the results less significant due to the need of correcting for multiple testing. Thus, study design in 
genetic association studies needs to accomplish the goal of being hypothesis-free with a limited 
number of hypotheses tested.  
 With the aforementioned difficulties in mind, we have focused in the last 5 years on the 
characterization of a secreted protein, namely bactericidal/permeability-increasing fold-containing 
family B member 4 (BPIFB4) that emerged from a GWAS on an Italian set of LLIs and was 
validated in a subsequent follow up done on two independent populations from Germany and USA. 
Data showed the consistent enrichment for homozygous for the minor allele rs2070325 (I229V) of 
BPIFB4 in LLIs. The BPIFB4 locus is under balancing selection. (i.e. it is enriched of highly 
frequent polymorphisms as consequence of an evolutionary force) and it is characterized by high 
levels of Linkage disequilibrium that has been described between rs2070325 polymophism and 
additional three polymorphisms (19). Thus, the rs2070325 variation (Ile229Val) of BPIFB4 
(identifier: P59827.2) is strongly correlated with rs2889732 (Asn281Thr), rs11699009 (Leu488Phe) 
and rs11696307 (Ile494Thr) generating two alternative haplotypes: WT 
(Ile229/Asn281/Leu488/Ile494-BPIFB4) and LAV (Val229/Thr281/Phe488/Thr494) isoforms.  
BPIFB4 is expressed in undifferentiated and highly proliferative tissues, and in pathologic 
conditions like cardiac hypertrophy. The mechanism of action of BPIFB4 still remains unclear but 
its overexpression induces activation of the stress response (HSPs) and protein homeostasis 
(translation, ribosome biogenesis, spliceosome). Since these two processes promoted by BPIFB4 
are lost during aging leading to apoptosis and contributing to age-related dysfunction of endothelial 
cells (20), we postulate a role of BPIFB4 in healthy cardiovascular aging. In line with this 
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hypothesis, BPIFB4 serum levels are higher in healthy-LLIs compared to frail-LLIs and young 
controls (21). Similar differences are seen in CD34+ progenitor cells of LLIs, which expressed 
higher levels of BPIFB4 RNA than cells from young controls (19). Hence, the expression of 
BPIFB4 is somehow related to both increased life expectancy and reparative cells activation. 
Importantly, old mice showed a decline of BPIFB4 expression at the vessels level as compared to 
young animals (19). In addition, we showed that mononuclear cells (MNCs) isolated from a/a 
homozygous carriers for rs2070325 (LAV) had higher levels of activated eNOS than non-carriers 
pointing to beneficial effects of LAV genotype and an involvement of eNOS in the LAV-associated 
benefit. Indeed, in vivo administered LAV-BPIFB4 improved eNOS activity and endothelial 
function measured in explanted mesenteric vessels, and reduced blood pressure in both young and 
old mice. To be noted, the above mentioned therapeutic effects were not observed with the 
administration of the WT-BPIFB4, reinforcing the genetic finding and the protective role of LAV 
genotype. BPIFB4 knock down in isolated vessels showed decreased eNOS and impaired 
endothelial function further confirming a central role of BPIFB4 in eNOS modulation. Adeno 
Associated Virus- (AAV)-LAV-BPIFB4 therapy in old mice showed a full recovery of both 
endothelial function and eNOS activity, to levels comparable to the young mice.  
The mechanism underpinning the eNOS activation by LAV-BPIFB4 needs further 
investigation. Initial observations from our group indicate that LAV-BPIFB4 phosphorylation at 
serine 75 by the stress kinase PERK regulates the recruitment of 14-3-3 and heat Shock Protein 
(HSP90), which together interact with eNOS and other proteins forming an activated complex that 
cooperates to NO generation (Figure 1). Of note, LAV-BPIFB4 is involved in angiogenesis 
promotion. Intravenous injection of LAV-BPIFB4 supports reparative vasculogenesis and enhances 
the recruitment and homing of circulating proangiogenic cells in a mouse model of limb ischemia. 
Furthermore, LAV-BPIFB4 therapy induced VEGF-A together with Superoxide dismutase 2 
(SOD2)/Superoxide dismutase 3 (SOD3) expression in ischemic muscles (19). These data link the 
expression of LAV-BPIFB4 in LLIs with a greater availability of proangiogenic cells, a higher 
antioxidant efficiency, and activation of molecular pathways crucial to an efficient angiogenesis.  
 
5. Conclusions 
In ancient times, explorers have incessantly searched for the fountain of youth, a source of magical 
water capable of reversing the aging process. This was the motivational tactic for the King 
Ferdinand’s crew leading to the eventual discovery of Florida. By 2020, for the first time in history, 
people ≥65 years of age will outnumber children (<5 years of age) in the world. Therefore, 
scientists are urgently asked to find solutions to maintain the old population healthy and active. 
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Identifying genetic variations in centenarians might represent the winning strategy to treat or 
prevent the onset of diseases at earlier stages of life and aid in the discovery of new pathways to 
promote longevity with less disease. We have provide prototypical examples of such an approach. 
Further studies are necessary to validate the therapeutic and safety profile of BPIFB4 therapy in 
large animals before starting a definitive experimentation in a first-in-man clinical trial for CVD. 
 
Figure Legends 
Figure 1. Mechanism of action of the longevity-associated variant (LAV) of BPIFB4. A) 
Cellular stress induces protein kinase RNA-like endoplasmic reticulum kinase (PERK) activation 
with subsequent phosphorylation of LAV-BPIFB4, which then binds to the 14-3-3 protein. B) The 
14.3.3/LAV BPIFB4 complex selectively binds phosphorylated endothelial nitric oxide synthase 
(eNOS) the activation of which is mediated by a yet to be identified kinase (question mark). Other 
players, such as heat shock protein (HSP) 90, are recruited to increase the production of nitric oxide 
(NO). Increased NO production enhances endothelial function and promotes angiogenesis. 
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